Breaking News Instant updates and real-time market news.

AMGN

Amgen

$173.27

-0.05 (-0.03%)

, DNA

Bought by RHHBY

07:51
07/13/17
07/13
07:51
07/13/17
07:51

FDA Oncologic Drugs Advisory Committee to hold a meeting

The Committee will discuss during the morning session, Genentech/Roche's AVASTIN (bevacizumab), submitted by Amgen, the Biologics License Application (BLA) 761028 for ABP 215 a proposed biosimilar. During the afternoon session, the Committee discusses Biologics License Application (BLA) 761074 for MYL-1401O, a proposed biosimilar to Genentech's HERCEPTIN (trastuzumab), submitted by Mylan. The meeting will be held at the FDA Silver Spring, MD offices on July 13 at 8 am. Webcast Link

AMGN

Amgen

$173.27

-0.05 (-0.03%)

DNA

Bought by RHHBY

MYL

Mylan

$38.58

0.93 (2.47%)

RHHBY

Roche

$31.51

0.55 (1.78%)

  • 13

    Jul

  • 19

    Jul

  • 25

    Jul

  • 30

    Jul

  • 14

    Aug

  • 03

    Sep

  • 11

    Sep

  • 14

    Sep

  • 09

    Oct

  • 03

    Feb

AMGN Amgen
$173.27

-0.05 (-0.03%)

06/22/17
LEER
06/22/17
NO CHANGE
LEER
Leerink sees reasons for biotech rally to continue
Leerink analyst Geoffrey Porges attributes the recent strength in the biotech sector to a lessening of the perceived fears of pricing regulations and a favorable tone from the FDA. However, he believes the sector could advance at least 15% more, as he foresees more positive operating results and still expects more industry consolidation. Among large cap biotech names, Porges maintains Outperform ratings on Regeneron (REGN), Celgene (CELG), Vertex (VRTX) and Alexion(ALXN) and keeps Market Perform ratings on AbbVie (ABBV), Amgen (AMGN), Gilead (GILD) and Biogen (BIIB).
06/23/17
DBAB
06/23/17
INITIATION
Target $172
DBAB
Hold
Amgen initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Andrew Peters started Amgen with a Hold rating and $172 price target, saying its valuation is largely in line with its near-term growth challenges.
06/23/17
06/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Starbucks (SBUX) initiated with an Overweight at KeyBanc. 2. Wix.com (WIX) initiated with an Outperform at Wedbush. 3. Red Hat (RHT) initiated with a Neutral at Piper Jaffray. 4. Amgen (AMGN) initiated with a Hold at Deutsche Bank. 5. Oclaro (OCLR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/10/17
JEFF
07/10/17
INITIATION
Target $195
JEFF
Buy
Amgen assumed with a Buy at Jefferies
Jefferies analyst Michael Yee assumed coverage on Amgen with a Buy and a $195 price target.
DNA Bought by RHHBY

MYL Mylan
$38.58

0.93 (2.47%)

05/31/17
WELS
05/31/17
NO CHANGE
WELS
Market Perform
Pension fund campaign a short-term negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris believes the campaign by four major pension funds to oppose the re-election of six directors is short-term negative for Mylan but has the potential to be a longer term positive. The campaign may pose a distraction to management, but if successful, it could address some governance concerns regarding compensation and performance at the company, Maris tells investors in a research note. The analyst has a Market Perform rating on Mylan shares.
06/12/17
SBSH
06/12/17
NO CHANGE
Target $38
SBSH
Buy
Citi says CRL for Coherus not worst case scenario
Citi analyst Mohit Bansal says Coherus Biosciences' (CHRS) complete response letter for its biosimilar version of Neulasta, while "clearly a negative outcome," is not the worst case scenario since the FDA did not ask for another study. The analyst sees a one year delay, which impacts his discounted free cash flow model by $5 per share. Coherus in premarket trading is down 30%, or $6.25, to $14.40. A one year delay would mean Coherus' CHS-1701 could still be on markets at the same time as competition from Mylan (MYL) and ahead of Sandoz's approval in 2019, Bansal tells investors in a research note. The analyst has a Buy rating on Coherus with a $38 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $41
CANT
Neutral
Mylan initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Mylan with a Neutral rating and $41 price target.
06/21/17
WELS
06/21/17
NO CHANGE
WELS
Market Perform
Wells wouldn't be surprised to see greater scrutiny on Mylan coal tax credits
After a new report from Reuters questioned the way in which Mylan uses its ownership of coal processing plants to keep its taxes low, Wells Fargo analyst David Maris said this topic has interested him for some time but his questions to management on the issue were not answered. Maris, who said he would not be surprised to see greater public scrutiny on this issue after the report, keeps a Market Perform rating on Mylan shares.
RHHBY Roche
$31.51

0.55 (1.78%)

07/06/17
UBSW
07/06/17
DOWNGRADE
UBSW
Neutral
Roche downgraded to Neutral from Buy at UBS
UBS analyst Jack Scannell downgraded Roche to Neutral saying he's become more cautious on oncology in general and that the shares are close to his fair value estimate. The analyst has a CHF 260 price target for the shares.
07/07/17
DBAB
07/07/17
DOWNGRADE
DBAB
Hold
Roche downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Tim Race downgraded Roche to Hold saying the risk/reward is "now finely balanced" given the stock's year-to-date performance. He believes his expectation for 2017-2022 annual earnings growth of 4% no longer justifies a premium valuation. The analyst lowered his price target for the shares to CHF 260 from CHF 273.
07/11/17
FBCO
07/11/17
NO CHANGE
Target $96
FBCO
Outperform
Alnylam weakness more driven by competitor data, says Credit Suisse
While attending the ISTH meeting in Berlin, Credit Suisse analyst Alethia Young notes that Alnylam's (ALNY) stock weakness is more driven by "strong" competitor data in inhibitors from Roche's (RHHBY) ACE910. The analyst reiterates an Outperform rating and $96 price target on Alnylam's shares.
07/11/17
COWN
07/11/17
NO CHANGE
Target $325
COWN
Outperform
Shire hemophilia franchise being valued near zero, says Cowen
Cowen analyst Ken Cacciatore believes Shire's (SHPG) current valuation reflects essentially no value for the company's hemophilia franchise. Investors are treating Shire/Baxalta's hemophilia franchise as if it should equate to essentially zero, into perpetuity, beginning in 2020, Cacciatore tells investors in a research note, citing his analysis. He believes this sentiment, based on competitive concerns from Roche (RHHBY) and Alnylam (ALNY), is a "gross overreaction." The analyst has an Outperform rating on Shire with a $325 price target.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$29.18

-0.46 (-1.55%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Aclaris Therapeutics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Week of 7/28 Baker-Hughes…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

JAGX

Jaguar Animal Health

$0.66

-0.0175 (-2.58%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Jaguar Animal Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

CALM

Cal-Maine Foods

$38.05

0.55 (1.47%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
Cal-Maine Foods participates in a conference call with Stephens »

Stephens hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

, IBM

IBM

$145.07

-0.29 (-0.20%)

04:55
07/28/17
07/28
04:55
07/28/17
04:55
Conference/Events
RSA Security to hold a conference »

RSA Security Conference…

BAESY

BAE Systems

$32.23

0.145 (0.45%)

IBM

IBM

$145.07

-0.29 (-0.20%)

CTL

CenturyLink

$23.60

0.74 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Breaking General news story  »

Minneapolis Federal…

04:55
07/28/17
07/28
04:55
07/28/17
04:55
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

03:35
07/28/17
07/28
03:35
07/28/17
03:35
General news
FX Action: USD-CAD steady after posting its biggest one-day gain »

FX Action: USD-CAD steady…

01:40
07/28/17
07/28
01:40
07/28/17
01:40
General news
FX Update: The Swiss franc tumbled for a four straight session »

FX Update: The Swiss…

TOO

Teekay Offshore Partners

$2.55

-0.03 (-1.16%)

20:27
07/27/17
07/27
20:27
07/27/17
20:27
Downgrade
Teekay Offshore Partners rating change at Raymond James »

Teekay Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Downgrade
QEP Resources rating change at JPMorgan »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

RDFN

Redfin

20:26
07/27/17
07/27
20:26
07/27/17
20:26
Syndicate
Redfin 9.231M share IPO priced at $15.00 »

The deal range is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 28

    Jul

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

, CVX

Chevron

$106.11

0.99 (0.94%)

20:25
07/27/17
07/27
20:25
07/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

XOM

Exxon Mobil

$80.83

0.46 (0.57%)

CVX

Chevron

$106.11

0.99 (0.94%)

MRK

Merck

$63.69

1.89 (3.06%)

ABBV

AbbVie

$71.73

-0.86 (-1.18%)

AAL

American Airlines

$50.00

-1.01 (-1.98%)

COL

Rockwell Collins

$109.02

-0.53 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 28

    Jul

  • 07

    Aug

  • 28

    Aug

  • 22

    Sep

TTPH

Tetraphase

$6.96

-0.92 (-11.68%)

20:22
07/27/17
07/27
20:22
07/27/17
20:22
Syndicate
Tetraphase 10M share Secondary priced at $6.50 »

Piper Jaffray, BMO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

BVN

Buenaventura

$12.45

0.1 (0.81%)

19:26
07/27/17
07/27
19:26
07/27/17
19:26
Earnings
Buenaventura reports Q2 EPS (2c), may not compare to consensus 26c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:02
07/27/17
07/27
19:02
07/27/17
19:02
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

BAS

Basic Energy

$28.67

0.06 (0.21%)

19:01
07/27/17
07/27
19:01
07/27/17
19:01
Earnings
Basic Energy reports Q2 adjusted EPS (57c), consensus (55c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 14

    Aug

GE

General Electric

$25.79

0.2 (0.78%)

18:55
07/27/17
07/27
18:55
07/27/17
18:55
Periodicals
Breaking Periodicals news story on General Electric »

Uber CEO shortlists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AIV

Aimco

$44.01

0.13 (0.30%)

18:53
07/27/17
07/27
18:53
07/27/17
18:53
Earnings
Aimco reports Q2 AFFO 51c vs 50c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

NOV

National Oilwell

$33.71

0.37 (1.11%)

18:43
07/27/17
07/27
18:43
07/27/17
18:43
Earnings
National Oilwell reports Q2 adjusted EPS (14c), consensus (15c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 29

    Aug

AIG

AIG

$65.17

-0.02 (-0.03%)

, IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

18:39
07/27/17
07/27
18:39
07/27/17
18:39
Periodicals
Senators worried over whether Icahn is pushing regulators on AIG, Reuters says »

U.S. Democratic Senators…

AIG

AIG

$65.17

-0.02 (-0.03%)

IEP

Icahn Enterprises

$53.12

-0.78 (-1.45%)

PRU

Prudential

$112.74

0.55 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 03

    Aug

  • 27

    Sep

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

18:24
07/27/17
07/27
18:24
07/27/17
18:24
Earnings
Heritage Commerce reports Q2 EPS 19c, consensus 19c »

Reports Q2 NII $24.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.